Rushit N. Lodaya
Research Subjects
Rushit N. Lodaya has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Asma Ashraf
GSK, Rockville Centre for Vaccines Research, Rockville, MD 20850, USA
3 shared publications - Derek T. O'Hagan
GSK, Rockville Centre for Vaccines Research, Rockville, MD 20850, USA
3 shared publications - Mansoor M. Amiji
Northeastern University, USA
3 shared publications - Amey P. Kanitkar
GSK, Rockville Centre for Vaccines Research, Rockville, MD 20850, USA
2 shared publications Chathura Abeywickrama
University of Connecticut, School of Pharmacy, Storrs, CT 06269, USA
2 shared publications- Douty Bamba
GSK, Rockville Centre for Vaccines Research, Rockville, MD 20850, USA
2 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 284
Spray Freeze Drying for Solid Formulations of RNA Lipid Nanoparticles
Spray-freeze drying (SFD) is a promising drying technique for stabilizing RNA lipid nanoparticles (RNA-LNPs) by converting them into solid-state formulatio
- 9 September 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (7) , 284
Open AccessSpray Freeze Drying for Solid Formulations of RNA Lipid Nanoparticles
Spray-freeze drying (SFD) is a promising drying technique for stabilizing RNA lipid nanoparticles (RNA-LNPs) by converting them into solid-state formulatio
- 30 March 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 696, 126829
Spray freeze drying as a novel strategy to enhance oral delivery of proteins/peptides
- 30 March 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 696, 126829
Spray freeze drying as a novel strategy to enhance oral delivery of proteins/peptides
- Open Access
- 17 February 2026
- Published by Elsevier in SSRN Electronic Journal
Spray freeze drying as a novel strategy to enhance oral delivery of proteins/peptides
Mucoadhesive microparticles can prolong the intestinal residence time of challenging molecules (such as proteins and peptides), thereby enhancing their oral absorption. Spray freeze drying provides several advantages over conventional drying methods and is therefore a promising approach to produce mucoadhesive microparticles intended for oral delivery of thermolabile biomolecules. However, spray freeze drying is a complex process, and slight changes in the formulation and process parameters viz., excipients, primary drying time, and primary drying temperature can significantly affect the critical quality attributes (e.g., particle size and particle flow) of the spray freeze dried microparticles. FTIR analysis indicated stabilizing interactions between the peptide and selected excipients. Notably, excipients that crystallized during drying generally yielded particles with superior mechanical integrity and flow properties. Comparative evaluation of formulations prepared by different drying techniques showed that mannitol and the peptide crystallized in both the spray freeze dried and freeze-dried samples, whereas they remained amorphous after spray-drying. In vitro release and ex vivo mucoadhesion studies demonstrated that spray freeze dried microparticles can sustain peptide release and enhance intestinal residence time. For spray freeze drying, drug release and retention correlated with particle size and matrix porosity, underscoring the importance of considering these parameters during formulation design. This research represents the first systematic development of a robust spray freeze drying process for mucoadhesive microparticles and provides the first detailed assessment of excipient effects on the critical quality attributes. The knowledge gained from this research can guide the design of spray freeze dried systems for different drug-delivery applications.
- 17 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSpray freeze drying as a novel strategy to enhance oral delivery of proteins/peptides
Mucoadhesive microparticles can prolong the intestinal residence time of challenging molecules (such as proteins and peptides), thereby enhancing their oral absorption. Spray freeze drying provides several advantages over conventional drying methods and is therefore a promising approach to produce mucoadhesive microparticles intended for oral delivery of thermolabile biomolecules. However, spray freeze drying is a complex process, and slight changes in the formulation and process parameters viz., excipients, primary drying time, and primary drying temperature can significantly affect the critical quality attributes (e.g., particle size and particle flow) of the spray freeze dried microparticles. FTIR analysis indicated stabilizing interactions between the peptide and selected excipients. Notably, excipients that crystallized during drying generally yielded particles with superior mechanical integrity and flow properties. Comparative evaluation of formulations prepared by different drying techniques showed that mannitol and the peptide crystallized in both the spray freeze dried and freeze-dried samples, whereas they remained amorphous after spray-drying. In vitro release and ex vivo mucoadhesion studies demonstrated that spray freeze dried microparticles can sustain peptide release and enhance intestinal residence time. For spray freeze drying, drug release and retention correlated with particle size and matrix porosity, underscoring the importance of considering these parameters during formulation design. This research represents the first systematic development of a robust spray freeze drying process for mucoadhesive microparticles and provides the first detailed assessment of excipient effects on the critical quality attributes. The knowledge gained from this research can guide the design of spray freeze dried systems for different drug-delivery applications.
- Open Access
Microfluidic-Chip-Based Formulation and In Vivo Evaluations of Squalene Oil Emulsion Adjuvants for Subunit Vaccines
Background: Adjuvants play a crucial role in improving the immunogenicity of various antigens in vaccines. Squalene-in-water emulsions are clinically established vaccine adjuvants that improve immune responses, particularly during a pandemic. Current manufacturing processes for these emulsion adjuvants include microfluidizers and homogenizers and these processes have been used to produce emulsion adjuvants to meet global demands during a pandemic. These processes, however, are complex and expensive and may not meet the global needs based on the growing populations in low- and middle-income countries. At the forefront of adjuvant research, there is a pressing need to manufacture emulsion adjuvants using novel approaches that balance efficacy, scalability, speed of production, and cost-effectiveness. Methods: In this study, we explored the feasibility of a microfluidic chip platform to address these challenges and evaluated the adjuvanticity of the emulsion adjuvant prepared using the microfluidic chip process in CB6F1 mice model, and compared it with a control formulation. We developed and optimized the process parameters to produce emulsion adjuvants with characteristics similar to SEA160 (control formulation). Results: The resulting emulsion prepared using the microfluidic chip process (MC160) when mixed with ovalbumin, maintained antigen structural integrity. Immunogenicity studies in a CB6F1 mouse model, with the Cytomegalovirus glycoprotein B (CMV gB) antigen, resulted in humoral responses that were non-inferior between MC160 and SEA160, thereby validating the microfluidic chip approach for manufacturing emulsion adjuvants. Conclusions: These findings demonstrate a proof of concept for using microfluidic chip platforms for formulating emulsion adjuvants, offering a simpler manufacturing platform that can be deployed to low- and middle-income countries for rapid production, improving adjuvant access and aiding in pandemic preparedness.
Open AccessMicrofluidic-Chip-Based Formulation and In Vivo Evaluations of Squalene Oil Emulsion Adjuvants for Subunit Vaccines
Background: Adjuvants play a crucial role in improving the immunogenicity of various antigens in vaccines. Squalene-in-water emulsions are clinically established vaccine adjuvants that improve immune responses, particularly during a pandemic. Current manufacturing processes for these emulsion adjuvants include microfluidizers and homogenizers and these processes have been used to produce emulsion adjuvants to meet global demands during a pandemic. These processes, however, are complex and expensive and may not meet the global needs based on the growing populations in low- and middle-income countries. At the forefront of adjuvant research, there is a pressing need to manufacture emulsion adjuvants using novel approaches that balance efficacy, scalability, speed of production, and cost-effectiveness. Methods: In this study, we explored the feasibility of a microfluidic chip platform to address these challenges and evaluated the adjuvanticity of the emulsion adjuvant prepared using the microfluidic chip process in CB6F1 mice model, and compared it with a control formulation. We developed and optimized the process parameters to produce emulsion adjuvants with characteristics similar to SEA160 (control formulation). Results: The resulting emulsion prepared using the microfluidic chip process (MC160) when mixed with ovalbumin, maintained antigen structural integrity. Immunogenicity studies in a CB6F1 mouse model, with the Cytomegalovirus glycoprotein B (CMV gB) antigen, resulted in humoral responses that were non-inferior between MC160 and SEA160, thereby validating the microfluidic chip approach for manufacturing emulsion adjuvants. Conclusions: These findings demonstrate a proof of concept for using microfluidic chip platforms for formulating emulsion adjuvants, offering a simpler manufacturing platform that can be deployed to low- and middle-income countries for rapid production, improving adjuvant access and aiding in pandemic preparedness.
- Open Access
- 10 January 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 238
A Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated with a Recombinant Cytomegalovirus (CMV) Pentamer Antigen in Mice
The development of new vaccine adjuvants represents a key approach to improvingi the immune responses to recombinant vaccine antigens. Emulsion adjuvants, such as AS03 and MF59, in combination with influenza vaccines, have allowed antigen dose sparing, greater breadth of responses and fewer immunizations. It has been demonstrated previously that emulsion adjuvants can be prepared using a simple, low-shear process of self-emulsification (SE). The role of alpha tocopherol as an immune potentiator in emulsion adjuvants is clear from the success of AS03 in pandemic responses, both to influenza and COVID-19. Although it was a significant formulation challenge to include alpha tocopherol in an emulsion prepared by a low-shear process, the resultant self-emulsifying adjuvant system (SE-AS) showed a comparable effect to the established AS03 when used with a quadrivalent influenza vaccine (QIV). In this paper, we first optimized the SE-AS with alpha tocopherol to create SE-AS44, which allowed the emulsion to be sterile-filtered. Then, we compared the in vitro cell activation cytokine profile of SE-AS44 with the self-emulsifying adjuvant 160 (SEA160), a squalene-only adjuvant. In addition, we evaluated SE-AS44 and SEA160 competitively, in combination with a recombinant cytomegalovirus (CMV) pentamer antigen mouse.
- 10 January 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 238
Open AccessA Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated with a Recombinant Cytomegalovirus (CMV) Pentamer Antigen in Mice
The development of new vaccine adjuvants represents a key approach to improvingi the immune responses to recombinant vaccine antigens. Emulsion adjuvants, such as AS03 and MF59, in combination with influenza vaccines, have allowed antigen dose sparing, greater breadth of responses and fewer immunizations. It has been demonstrated previously that emulsion adjuvants can be prepared using a simple, low-shear process of self-emulsification (SE). The role of alpha tocopherol as an immune potentiator in emulsion adjuvants is clear from the success of AS03 in pandemic responses, both to influenza and COVID-19. Although it was a significant formulation challenge to include alpha tocopherol in an emulsion prepared by a low-shear process, the resultant self-emulsifying adjuvant system (SE-AS) showed a comparable effect to the established AS03 when used with a quadrivalent influenza vaccine (QIV). In this paper, we first optimized the SE-AS with alpha tocopherol to create SE-AS44, which allowed the emulsion to be sterile-filtered. Then, we compared the in vitro cell activation cytokine profile of SE-AS44 with the self-emulsifying adjuvant 160 (SEA160), a squalene-only adjuvant. In addition, we evaluated SE-AS44 and SEA160 competitively, in combination with a recombinant cytomegalovirus (CMV) pentamer antigen mouse.
- Open Access
- 7 November 2022
- Published by MDPI AG in Preprints.org
A Self-Emulsified Adjuvant System Containing Alpha-Tocopherol Induced Higher Neutralizing Antibody Responses than a Squalene Only Emulsion Against a Recombinant Cytomegalovirus (CMV) Pentamer Antigen
Research for novel vaccine adjuvants remains a critical need to improve the immune responses to a recombinant vaccine antigen. Emulsion adjuvants such as AS03 and MF59, particularly in the area of Influenza vaccines, have shown antigen dose sparing and allowed reduced immunizations. It was previously demonstrated that these emulsion adjuvants can be formulated using a simpler, low shear process of self-emulsification. The role of alpha tocopherol as an immunomodulator in emulsion adjuvants is evident from the success of AS03 in the on-going covid-19 pandemic. Although, it was a challenge to formulate alpha tocopherol with a low shear process to get closer to the AS03 composition, the self-emulsified version referred as self-emulsifying adjuvant systems (SE-AS) showed comparable immune responses to AS03 when co-administered with a Quadrivalent influenza virus (QIV) vaccine. In this paper, we first optimized the SE-AS with alpha tocopherol referred to as SE-AS44 to allow sterile filtration. We compared the in vitro cytokine profile with self-emulsifying adjuvant 160 (SEA160), a squalene-only self-emulsified adjuvant with composition similar to MF59. We compared SE-AS44 and SEA160 co-administered with a recombinant cytomegalovirus (CMV) pentamer antigen, which is a less immunogenic antigen, in vivo to compare the antibody and T-cell responses, in different adjuvanted groups, in C57BL/6 mice.
- 7 November 2022
- Published by MDPI AG in Preprints.org
Open AccessA Self-Emulsified Adjuvant System Containing Alpha-Tocopherol Induced Higher Neutralizing Antibody Responses than a Squalene Only Emulsion Against a Recombinant Cytomegalovirus (CMV) Pentamer Antigen
Research for novel vaccine adjuvants remains a critical need to improve the immune responses to a recombinant vaccine antigen. Emulsion adjuvants such as AS03 and MF59, particularly in the area of Influenza vaccines, have shown antigen dose sparing and allowed reduced immunizations. It was previously demonstrated that these emulsion adjuvants can be formulated using a simpler, low shear process of self-emulsification. The role of alpha tocopherol as an immunomodulator in emulsion adjuvants is evident from the success of AS03 in the on-going covid-19 pandemic. Although, it was a challenge to formulate alpha tocopherol with a low shear process to get closer to the AS03 composition, the self-emulsified version referred as self-emulsifying adjuvant systems (SE-AS) showed comparable immune responses to AS03 when co-administered with a Quadrivalent influenza virus (QIV) vaccine. In this paper, we first optimized the SE-AS with alpha tocopherol referred to as SE-AS44 to allow sterile filtration. We compared the in vitro cytokine profile with self-emulsifying adjuvant 160 (SEA160), a squalene-only self-emulsified adjuvant with composition similar to MF59. We compared SE-AS44 and SEA160 co-administered with a recombinant cytomegalovirus (CMV) pentamer antigen, which is a less immunogenic antigen, in vivo to compare the antibody and T-cell responses, in different adjuvanted groups, in C57BL/6 mice.
- Open Access
- 1 December 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 316, 12-21
Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine
- 1 December 2019
- Published by Elsevier in Journal of Controlled Release
- Vol. 316, 12-21
Open AccessFormulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine